A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Relapsing/Refractory Multiple Sclerosis

The study consists of three dose groups as follows: Dose Level 1: Total dose of 8.5 mg, administered via 4 separate intravenous infusions at doses of 1.0 mg, 1.5 mg, 3.0 mg and 3.0 mg; Dose Level 2: Total dose of 13.5 mg, administered via 4 separate intravenous infusions at doses of 1.5 mg, 3.0 mg, 4.5 mg and 4.5 mg; De-escalation Dose: Total dose of 4.5 mg, administered via 4 separate intravenous infusions at doses of 0.5 mg, 1.0 mg, 1.5 mg and 1.5 mg. It is planned to enroll 4-12 participants in total. The planned number of participants for each dose group is specified below: Dose Level 1: 1-6 participants; Dose Level 2: 3-6 participants; De-escalation Dose: 1-6 participants.